Literature DB >> 21233829

EZH2 Y641 mutations in follicular lymphoma.

C Bödör, C O'Riain, D Wrench, J Matthews, S Iyengar, H Tayyib, M Calaminici, A Clear, S Iqbal, H Quentmeier, H G Drexler, S Montoto, A T Lister, J G Gribben, A Matolcsy, J Fitzgibbon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21233829     DOI： 10.1038/leu.2010.311

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  61 in total

Review 1.  Epigenetic dysregulation in follicular lymphoma.

Authors:  Shamzah Araf; Jessica Okosun; Lola Koniali; Jude Fitzgibbon; James Heward
Journal:  Epigenomics       Date:  2015-12-23       Impact factor: 4.778

Review 2.  Mechanisms of epigenetic deregulation in lymphoid neoplasms.

Authors:  Yanwen Jiang; Katerina Hatzi; Rita Shaknovich
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

3.  The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum.

Authors:  S Momose; S Weißbach; J Pischimarov; T Nedeva; E Bach; M Rudelius; E Geissinger; A M Staiger; G Ott; A Rosenwald
Journal:  Leukemia       Date:  2015-02-12       Impact factor: 11.528

Review 4.  Novel agents in follicular lymphoma: choosing the best target.

Authors:  Laurie H Sehn
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 5.  Epigenetic Control of B Cell Development and B-Cell-Related Immune Disorders.

Authors:  Yan Bao; Xuetao Cao
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

Review 6.  Emerging EZH2 Inhibitors and Their Application in Lymphoma.

Authors:  Jennifer K Lue; Jennifer E Amengual
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

Review 7.  Epigenetics and B-cell lymphoma.

Authors:  Rita Shaknovich; Ari Melnick
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

8.  FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.

Authors:  Anja Mottok; Vindi Jurinovic; Pedro Farinha; Andreas Rosenwald; Ellen Leich; German Ott; Heike Horn; Wolfram Klapper; Michael Boesl; Wolfgang Hiddemann; Christian Steidl; Joseph M Connors; Laurie H Sehn; Randy D Gascoyne; Eva Hoster; Oliver Weigert; Robert Kridel
Journal:  Blood       Date:  2017-11-09       Impact factor: 22.113

9.  Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.

Authors:  X Zhao; T Lwin; X Zhang; A Huang; J Wang; V E Marquez; S Chen-Kiang; W S Dalton; E Sotomayor; J Tao
Journal:  Leukemia       Date:  2013-03-29       Impact factor: 11.528

Review 10.  Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.

Authors:  Xuejiao Tian; Saiyang Zhang; Hong-Min Liu; Yan-Bing Zhang; Christopher A Blair; Dan Mercola; Paolo Sassone-Corsi; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.